Medication and Exercise Interactions: Considering and Managing Hypoglycemia Risk

Shahar, Jacqueline; Hamdy, Osama
January 2015
Diabetes Spectrum;Winter2015, Vol. 28 Issue 1, p64
Academic Journal
The article discusses medication management considerations in people with diabetes who are engaged in exercise, with dependence on antihyperglycemic medications. Topics discussed, include additive pathways to stimulate glucose uptake by muscles via translocation of glucose transport proteins, increase in hypoglycemia risk during exercise by the use of insulin and challenges associated with glucose management as exercise have variable effects on blood glucose levels.


Related Articles

  • Insulin Aspart (rDNA Origin) Injection.  // AHFS Consumer Medication Information;May2020, p1 

    Insulin aspart is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and therefore...

  • Exercise as Medicine for Diabetes: Prescribing Appropriate Activities and Avoiding Potential Pitfalls. Colberg, Sheri R. // Diabetes Spectrum;Winter2015, Vol. 28 Issue 1, p10 

    The article discusses benefits of regular exercise and appropriate physical activities for people with diabetes. Topics discussed, include health benefits of exercise, impact of exercise on body metabolism, various research studies on the management of diabetes through exercise and maximizing...

  • Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Ip Tim Lau; Ka Fai Lee; Wing Yee So; Tan, Kathryn; Vincent Tok Fai Yeung // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Jun2017, Vol. 10, p273 

    Objective: To review published clinical studies on the efficacy and safety of new insulin glargine 300 units/mL (Gla-300), a new long-acting insulin analog, for the treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM). Materials and methods: Data sources comprised primary research...

  • Insulin Glulisine (rDNA origin) Injection.  // AHFS Consumer Medication Information;May2020, p1 

    Insulin glulisine is used to treat type 1 diabetes (condition in which the body does not make insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the blood sugar is too high because the body does not...

  • Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. Dardano, Angela; Bianchi, Cristina; Del Prato, Stefano; Miccoli, Roberto // Vascular Health & Risk Management;2014, Vol. 10, p465 

    Glycemic control remains the major therapeutic objective to prevent or delay the onset and progression of complications related to diabetes mellitus. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. Nevertheless, a large...

  • Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Dailey, George; Rosenstock, Julio; Moses, Robert G.; Ways, Kirk // Diabetes Care;Oct2004, Vol. 27 Issue 10, p2363 

    Objective: Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin.Research Design and Methods: In total,...

  • Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. RIDDLE, MATTHEW C.; FORST, THOMAS; ARONSON, RONNIE; SAUQUE-REYNA, LEOBARDO; SOUHAMI, ELISABETH; SILVESTRE, LOUISE; LIN PING; ROSENSTOCK, JULIO // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2497 

    OBJECTIVE--When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial. We examined the efficacy and safety of...

  • A 10-s Sprint Performed After Moderate-Intensity Exercise Neither Increases nor Decreases the Glucose Requirement to Prevent Late-Onset Hypoglycemia in Individuals With Type 1 Diabetes. DAVEY, RAYMOND J.; BUSSAU, VANESSA A.; PARAMALINGAM, NIRUBASINI; FERREIRA, LUIS D.; EE MUN LIM; DAVIS, ELIZABETH A.; JONES, TIMOTHY W.; FOURNIER, PAUL A. // Diabetes Care;Dec2013, Vol. 36 Issue 12, p4163 

    OBJECTIVE--To determine whether performing a 10-s sprint after moderate-intensity exercise increases the amount of carbohydrate required to maintain euglycemia and prevent late-onset postexercise hypoglycemia relative to moderate-intensity exercise alone. RESEARCH DESIGN AND METHODS--Seven...

  • New Options in Insulin Therapy. SARAIYA, NIDHI; MARTIN, SPENCER T. // Connecticut Medicine;Oct2015, Vol. 79 Issue 9, p553 

    The article presents a study on the options of using insulin therapy for the treatment of type 1 diabetes mellitus (TlDM) and type 2 diabetes mellitus (T2DM). Topics discussed include the approval of the insulin glargine 300 units/mL formulation by the U.S. Food and Drug Administration (FDA),...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics